17
MAY
2012
Northwest Bio Provides Update On DCVax® -L Brain Cancer Trial
Comments : Off
Amendment Accepted By FDA, Enhancing and Upgrading the Trial 41 US Clinical Trial Sites Now In Operation BETHESDA, MD, May 17, 2012 — Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) announced today that it now has 41 clinical trial sites open and recruiting across the United States in its ongoing clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. This is ahead of the... Read More